OptimizeRx Corp. (NASDAQ:OPRX) Position Boosted by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 47.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 124,751 shares of the company's stock after acquiring an additional 39,969 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.67% of OptimizeRx worth $1,080,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC acquired a new position in shares of OptimizeRx during the 1st quarter worth $33,000. SBI Securities Co. Ltd. acquired a new position in shares of OptimizeRx during the 4th quarter worth about $25,000. Wells Fargo & Company MN lifted its holdings in shares of OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after buying an additional 2,797 shares during the last quarter. Graham Capital Management L.P. acquired a new position in OptimizeRx during the 4th quarter valued at $81,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of OptimizeRx by 504.6% in the fourth quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock valued at $108,000 after buying an additional 18,618 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Stock Performance

Shares of OptimizeRx stock opened at $13.64 on Monday. OptimizeRx Corp. has a 12 month low of $3.78 and a 12 month high of $15.71. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $252.34 million, a PE ratio of -16.24, a PEG ratio of 4.55 and a beta of 1.33. The stock's fifty day simple moving average is $11.68 and its 200 day simple moving average is $8.16.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. On average, research analysts predict that OptimizeRx Corp. will post -0.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OPRX. Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, JMP Securities raised their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, OptimizeRx presently has a consensus rating of "Moderate Buy" and an average price target of $10.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.